BRAF V600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy.

MLA

Porcelli, Letizia, et al. “BRAF V600E;K601Q Metastatic Melanoma Patient-Derived Organoids and Docking Analysis to Predict the Response to Targeted Therapy.” Pharmacological Research, vol. 182, Aug. 2022, p. 106323. EBSCOhost, https://doi.org/10.1016/j.phrs.2022.106323.

APA

Porcelli, L., Di Fonte, R., Pierri, C. L., Fucci, L., Saponaro, C., Armenio, A., Serratì, S., Strippoli, S., Fasano, R., Volpicella, M., Daprile, R., Tommasi, S., Ressa, C. M., Guida, M., & Azzariti, A. (2022). BRAF V600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy. Pharmacological Research, 182, 106323. https://doi.org/10.1016/j.phrs.2022.106323

Chicago

Porcelli, Letizia, Roberta Di Fonte, Ciro L Pierri, Livia Fucci, Concetta Saponaro, Andrea Armenio, Simona Serratì, et al. 2022. “BRAF V600E;K601Q Metastatic Melanoma Patient-Derived Organoids and Docking Analysis to Predict the Response to Targeted Therapy.” Pharmacological Research 182 (August): 106323. doi:10.1016/j.phrs.2022.106323.